Trials / Completed
CompletedNCT04080609
DDI Study Between Dorzagliatin and Rifampicin
A Single Dose, Open Label, Drug-drug Interaction Study to Investigate the Pharmacokinetics and Safety of Dorzagliation Administered Alone or in Combination With Rifampicin in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Hua Medicine Limited · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this drug-drug interaction study is to investigate the impact of rifampicin on the pharmacokinetics of Dorzagliatin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dorzagliatin | GKA currently under clinical development |
Timeline
- Start date
- 2018-03-27
- Primary completion
- 2018-04-17
- Completion
- 2018-04-17
- First posted
- 2019-09-06
- Last updated
- 2019-09-06
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04080609. Inclusion in this directory is not an endorsement.